NCCN, AstraZeneca Projects Target Advanced Ovarian Cancer Patients

NCCN, AstraZeneca Projects Target Advanced Ovarian Cancer Patients
0
(0)

Four projects chosen by the National Comprehensive Cancer Network’s (NCCN) Oncology Research Program will explore ways to use technology to improve care for advanced ovarian cancer patients.

Funded by AstraZeneca, the two-year projects will begin the third quarter of this year. They are expected to provide measurable outcome steps, and be reproducible, scalable and swiftly implemented.

Advanced ovarian cancer means the malignancy has spread outside the ovaries.

“Advanced and recurrent ovarian cancer is currently the deadliest gynecologic cancer,” Wui-Jin Koh, MD, chief medical officer, NCCN, said in a press release. “It requires a multidisciplinary approach for management, which can provide challenges for optimal coordination. These projects will explore opportunities to leverage technology in order to improve patient outcomes and quality of life through supportive services, shared decision making, and innovative methods of care delivery,” he said.

The projects also will emphasize strategies intended to help close disparity gaps in ovarian cancer healthcare delivery, he said.

Cary Gross, MD, of Yale School of Medicine’s  Cancer Outcomes, Public Policy, and Effectiveness Research Center, will lead a project titled “CommunityRx-Cancer: An IT-enhanced Patient Navigation Program for Social Determinants of Health in Advanced Ovarian Cancer.”

In another project, Haller J. Smith, MD, of the University of Alabama at Birmingham, will work on “Feasibility and Impact of a Comprehensive Telehealth Program on Reducing Geographic Barriers to Treatment and Improving Symptom Management in Rural Patients with Advanced Ovarian Cancer.”

Barbara Goff, MD, and Donna L. Berry, PhD, RN, of the Fred Hutchinson Cancer Research Center in Seattle, Washington, have a project called “Patient-Centered Education and Support for Women with Advanced Ovarian Cancer.”

The fourth project, “Revitalize: A Telehealth Intervention for Women with Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue,” will be led by Alexi A. Wright, MD, and Hanneke Poort, PhD, Dana-Farber Cancer Institute in Boston, Massachusetts.

“Approximately 22,000 women in the U.S. are diagnosed with ovarian cancer each year, making it the fifth leading cause of cancer deaths among women,” said Adrian Kilcoyne, MD, vice president, U.S. Medical Affairs, AstraZeneca. “We are pleased to partner with NCCN in support of this important work in ovarian cancer. AstraZeneca’s commitment to eliminating cancer as a cause of death must extend beyond innovative medicines and include partnerships that seek to improve the quality of cancer care for patients.”

The NCCN is a nonprofit alliance of 28 leading cancer centers focused on patient care, research and education. Its Oncology Research Program seeks to improve the lives of cancer patients, and supports research and quality improvement projects in oncology at NCCN member institutions.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 129
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • Newk's Cares fundraising
  • pap smears and cancer diagnosis

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?